Taro Pharmaceutical Indus Q2 2023 Adj.EPS $0.38 Beats $0.18 Estimate, Sales $148.20M Miss $161.14M Estimate
Portfolio Pulse from saritha@benzinga.com
Taro Pharmaceutical Indus (NYSE:TARO) reported Q2 2023 earnings of $0.38 per share, beating the analyst consensus estimate of $0.18 by 111.11%. However, this is a 42.42% decrease from the same period last year. The company's quarterly sales of $148.20 million missed the analyst consensus estimate of $161.14 million by 8.03%, but it's a 13.57% increase from the same period last year.
October 26, 2023 | 9:11 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Taro Pharmaceutical's Q2 2023 earnings beat estimates but sales missed. The mixed results could lead to uncertainty in the market.
Taro Pharmaceutical's earnings beat estimates, which is a positive signal for investors. However, the company's sales missed estimates, which could be a concern. The decrease in earnings YoY might also worry investors. The mixed results could lead to uncertainty in the market, making it difficult to predict the short-term price direction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100